Feedback
Settings

Settings

Goto Application

124,304 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12,431
1.WO/2026/099807TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/IB2025/061397 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FERRIS, Robert, Louis
Provided herein is a method of treating a patient having a tumor, including determining whether one or more immune cells from the patient express an exhaustion phenotype and administering to the patient one or more therapeutic compositions, wherein: the therapeutic composition includes either one or more checkpoint inhibitors (ICIs) in an amount effective to treat the tumor when the one or more immune cells express the exhaustion phenotype or one or more compounds effective to prime the one or more immune cells to respond to one or more ICIs when the one or more cells do not express the exhaustion phenotype.
2.WO/2026/100257TREATMENT OF MALIGNANT TUMOR
WO - 15.05.2026
Int.Class A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
 Appl.No PCT/JP2025/034689 Applicant SYMBIO PHARMACEUTICALS LIMITED Inventor KAMITANI, Tetsu
Provided is a method for treating malignant tumor. Provided is a method for treating malignant tumor, the method comprising administering BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent to a subject. Alternatively, provided is a pharmaceutical composition for use in the treatment of malignant tumor, wherein the treatment comprises combination treatment to a subject with BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent, and wherein the pharmaceutical composition comprises BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, or an immunotherapeutic agent.
3.WO/2026/097722CHONDROGENIC STEM CELL FOR PROMOTING JOINT REPAIR AND USE THEREOF
WO - 15.05.2026
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
 Appl.No PCT/CN2025/077520 Applicant TONGJI UNIVERSITY Inventor YUE, Rui
Provided are a chondrogenic stem cell for promoting joint repair and use thereof. Specifically, disclosed is a cell preparation used for alleviating or treating osteoarthritis, comprising a Procr-positive pluripotent stem cell. The Procr-positive chondrogenic stem cell can differentiate and generate downstream chondrocytes in vivo and promote cartilage repair in osteoarthritis damage, which will be a more effective cell treatment method. In addition, Procr proteins can be used as a new target of a drug for treating osteoarthritis.
4.WO/2026/100725ANTI-CCR8 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
WO - 15.05.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/JP2025/039266 Applicant SUMITOMO PHARMA CO., LTD. Inventor UEMACHI Hiro
Provided is an antibody-drug conjugate represented by formula (1), or a pharmaceutically acceptable salt thereof. [wherein mAb represents an antibody that binds to CCR8, or a fragment thereof; n represents an integer from 1 to 8; L represents a group represented by formula (L-1), (L-2), (L-3) or (L-4); and Z represents a group represented by formula (Z-1), (Z-2) or (Z-3).]
5.WO/2026/099600ALVELESTAT IN THE TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS
WO - 15.05.2026
Int.Class A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
 Appl.No PCT/GB2025/052453 Applicant MEREO BIOPHARMA 4 LIMITED Inventor PARKIN, Jacqueline
The invention relates to medical uses of alvelestat, and pharmaceutically acceptable salts thereof, in the treatment of non-cystic fibrosis bronchiectasis.
6.WO/2026/097604COMPOSITION AND DRUG-DEVICE COMBINATION PRODUCT FOR LOCAL TUMOR ADMINISTRATION, AND USE
WO - 15.05.2026
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/CN2024/132474 Applicant NOMEDEL USA, LLC Inventor MAO, Shanhong Shane
A composition and drug-device combination product for local tumor injection, and the use thereof in the preparation of a drug for local tumor injection administration. The composition comprises an anti-tumor pharmaceutical ingredient, an immune adjuvant and a pharmaceutical carrier. By means of a specially designed jet microneedle delivery device, an anti-tumor drug can be locally administered to a tumor, thus avoiding the problem that traditional intravenous administration limits the maximum dose and therapeutic effect of the drug due to systemic toxicity. High-concentration local administration of the composition not only improves the local therapeutic effect on the tumor, but also can effectively produce a tumor antigen. In the subsequent course of treatment after the initial treatment, only a composition of an immune adjuvant and a tumor-specific polypeptide, or the immune adjuvant alone, can be administered to maintain and enhance the established tumor-specific immune response, avoiding the cumulative toxicity caused by repeated use of chemotherapeutic drugs.
7.WO/2026/101983COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF PREECLAMPSIA AND PREGNANCY ASSOCIATED HYPERTENSION
WO - 15.05.2026
Int.Class A61P 9/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
12Antihypertensives
 Appl.No PCT/US2025/054135 Applicant THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor BILLI, Allison
Provided herein compositions and methods for the treatment and prevention of preeclampsia or hypertensive disorders of pregnancy. In particular, provided herein are regulators of the Hippo pathway (e.g., TEAD inhibitors; VGLL2 regulators; verteporfin) that find use in the treatment and prevention of preeclampsia or hypertensive disorder of pregnancy.
8.WO/2026/098574DRUG FOR BRONCHOPULMONARY DYSPLASIA AND USE METHOD THEREFOR
WO - 15.05.2026
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/CN2025/133115 Applicant INTERNATIONAL PEACE MATERNITY AND CHILD HEALTH HOSPITAL OF CHINA WELFARE INSTITUTE Inventor FU, Xuemei
Provided in the present invention are an immunosuppressant and a method for treating and/or preventing bronchopulmonary dysplasia (BPD) in a subject, and use thereof. The immunosuppressant comprises an immunoglobulin inhibitor, a small molecule immunosuppressant, or a cell-type immunosuppressant, and the subject is preferably a premature newborn.
9.WO/2026/100539PHARMACEUTICAL COMPOSITION FOR PROMOTING MIGRATION OF SUBSTANCE TO CENTRAL NERVOUS SYSTEM
WO - 15.05.2026
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/JP2025/038603 Applicant ONO PHARMACEUTICAL CO., LTD. Inventor SHINDOU, Hideo
Provided is a composition for promoting migration of a target substance to the central nervous system, the composition containing a substance having an inhibitory activity against sphingomyelin synthase 1 (SMS1). Examples of the target substance include a compound, a peptide, a nucleic acid, a protein, an antibody, and a nucleic acid-containing vector, which are useful for preventing or treating central nervous system diseases.
10.WO/2026/101889ACYLOXYACYL HYDROLASE AND METHODS OF USE
WO - 15.05.2026
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
 Appl.No PCT/US2025/053940 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor JIANG, Peng
Methods of treating cancer in a subject by administering an AOAH protein, a nucleic acid encoding an AOAH protein, or a cell (such as an immune cell) expressing an AOAH protein are provided. AOAH proteins, fusion proteins, and nucleic acids encoding the AOAH proteins or fusion proteins are also provided. Methods of treating cancer in a subject by administering a LY86 protein, a nucleic acid encoding a LY86 protein, or a cell (such as an immune cell) expressing a LY86 protein are also provided. LY86 proteins, fusion proteins, and nucleic acids encoding the LY86 proteins or fusion proteins are further provided.
# -